Drug intelligence / Profile preview

ABS-202

Development stage: Preclinical
Lead developer: Absci
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

ABS-202 is an AI-designed monoclonal antibody developed by Absci that targets the prolactin receptor (PRLR). It is currently in preclinical development for the treatment of undisclosed immunology and inflammation (I&I) indications. By binding to and inhibiting PRLR, ABS-202 blocks prolactin-mediated signaling pathways, which are believed to play a role in modulating immune responses and inflammatory processes. The candidate was generated using Absci's proprietary Integrated Drug Creation platform, which utilizes generative AI to design and optimize therapeutic antibodies.

Targets

PRLR (Prolactin receptor)

Beyond the preview

Go deeper on ABS-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABS-202.

Explore the full profile